Merck & Co., Inc.

Name: Merck & Co., Inc. standardized financial statements, quarterly
Creator: Listed

MRKNYSECIK 310158HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$16.61bn, Q2 FY2026

Net income−$1.33bn, Q2 FY2026

Merck & Co., Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$bn	16.0	14.6	15.8	16.1	16.7	15.6	15.5	15.8	17.3	16.4	16.3	16.6
Cost of revenue	$bn	4.3	3.9	3.5	3.7	4.1	3.8	3.4	3.6	3.9	5.6	4.2	4.4
Research and development	$bn	3.3	9.6	4.0	3.5	5.9	4.6	3.6	4.0	4.2	3.9	12.6	9.7
Selling, general and administrative	$bn	2.5	2.8	2.5	2.7	2.7	2.9	2.6	2.6	2.6	2.9	2.7	2.9
Interest expense	$bn	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.5	0.5
Income tax	$bn	0.9	(0.8)	0.9	0.5	0.9	0.4	0.8	0.6	1.0	0.5	0.7	0.7
Net income	$bn	4.7	(1.2)	4.8	5.5	3.2	3.7	5.1	4.4	5.8	3.0	(4.2)	(1.3)
Diluted EPS	$ per share	1.86	not reported	1.87	2.14	1.24	not reported	2.01	1.76	2.32	not reported	(1.72)	(0.54)
Basic EPS	$ per share	1.87	not reported	1.88	2.15	1.25	not reported	2.01	1.76	2.32	not reported	(1.72)	(0.54)

Balance sheet

Cash and equivalents$6.85bn, Q2 FY2026

Long-term debt$51.08bn, Q2 FY2026

Shareholders' equity$41.93bn, Q2 FY2026

Merck & Co., Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$bn	8.6	6.8	5.6	11.3	14.6	13.2	8.6	8.0	18.2	14.6	5.3	6.8
Current assets	$bn	32.0	32.2	31.4	38.2	40.4	38.8	35.5	37.1	47.6	43.5	35.0	36.7
Total assets	$bn	107	107	106	113	118	117	115	118	130	137	129	130
Current liabilities	$bn	23.1	25.7	25.1	26.1	29.6	28.4	25.2	26.0	28.6	28.3	26.9	27.7
Long-term debt	$bn	34.0	33.7	31.1	34.7	35.0	34.5	33.5	34.0	40.0	46.8	46.7	51.1
Current portion of debt	$bn	0.9	1.3	3.1	3.1	3.1	2.5	1.4	1.4	1.4	2.3	2.4	2.8
Shareholders' equity	$bn	41.2	37.6	40.4	43.6	44.5	46.3	48.3	49.0	51.9	52.6	45.9	41.9

Cash flow

Operating cash flow$5.37bn, Q2 FY2026

Capital expenditure$893.0m, Q2 FY2026

Share repurchases$757.0m, Q2 FY2026

Merck & Co., Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	7,717	246	3,090	5,637	9,291	3,450	2,500	3,293	7,822	2,857	3,918	5,370
Capital expenditure	$m	902	989	861	791	783	937	1,328	764	987	1,033	991	893
Dividends paid	$m	1,855	1,852	1,950	1,986	1,953	1,951	2,050	2,077	2,031	2,018	2,105	2,144
Share repurchases	$m	466	393	122	251	444	489	1,164	1,345	1,323	1,252	874	757

Diluted shares (weighted)2.47bn, Q2 FY2026

Merck & Co., Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	2,542	2,551	2,539	2,546	2,544	2,544	2,541	2,531	2,513	2,498	2,472	2,470

Shares outstanding: 2.47bn at Jul 31, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. Listed shows no prices and gives no investment advice.